HER2+ Breast Cancer

The addition of an aromatase inhibitor (AI) to pertuzumab and trastuzumab improved progression-free survival by 3.09 months, when compared with trastuzumab plus an AI.

Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the ongoing progress with agents in development for the potential treatment of patients with HER2-positive breast cancer.

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the lasting impact that the CLEOPATRA and MARIANNE studies have had on the treatment landscape in HER2-positive breast cancer.

Mark Pegram, MD, sheds light on some of the recent groundbreaking trials in HER2-positive breast cancer and how they have come to shape the current treatment paradigm.

Kimberly L. Blackwell, MD, discusses the latest advances for patients with HER2-positive breast cancer and provides insight on the hurdles that still remain.

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.

A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses the overall treatment paradigm in the neoadjuvant setting of HER2-positive breast cancer.

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

Stephen K. Chia, MD, highlights the key findings from the KRISTINE and NSABP B-41 trials and their implications for the treatment of HER2-positive breast cancer.

Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.